KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Deffered Revenue (2016 - 2023)

Halozyme Therapeutics (HALO) has disclosed Non-Current Deffered Revenue for 14 consecutive years, with $2.3 million as the latest value for Q3 2023.

  • Quarterly Non-Current Deffered Revenue fell 20.47% to $2.3 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Sep 2023, down 20.47% year-over-year, with the annual reading at $2.3 million for FY2022, 10.95% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2023 was $2.3 million at Halozyme Therapeutics, roughly flat from $2.3 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $4.0 million in Q4 2020, with the low at $641000.0 in Q3 2020.
  • Average Non-Current Deffered Revenue over 5 years is $2.5 million, with a median of $2.4 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue plummeted 75.1% in 2019, then surged 294.7% in 2021.
  • Over 5 years, Non-Current Deffered Revenue stood at $1.2 million in 2019, then surged by 222.85% to $4.0 million in 2020, then crashed by 37.16% to $2.5 million in 2021, then dropped by 10.95% to $2.3 million in 2022, then changed by 0.0% to $2.3 million in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $2.3 million, $2.3 million, and $2.3 million for Q3 2023, Q2 2023, and Q1 2023 respectively.